Case Study

Addressing Glass Particulates In Injectable Drug Formulations

Vaccine Vial GettyImages-1216812369

Particulate contamination in drug formulations continues to be a cause for concern in the manufacture of injectable drugs and is a leading cause of injectable drug recalls. These recalls represent a significant cost and liability to drug manufacturers, placing significant value on any emerging technologies that can mitigate the risks of particulate generation and improve patient safety.

Glassmaker Corning has studied the root causes and engineered a new glass product in partnership with West Pharmaceutical Services, Inc. for use on existing equipment that significantly reduces that risk. Corning scientists determined significant particulate generation was the result of frictive sliding contact and impact events between vials on filling lines, opening the pathway to explore new materials and methods that substantially reduce this mechanism of glass particle contamination, thereby mitigating a risk for drug products.

A new vial made from an aluminosilicate glass composition and strengthened to provide superior strength is capable of reducing the propensity for glass particulate generation on filling lines. Examine the study to learn about the new vial design that uses a low coefficient-of-friction (COF) external surface to produce a significant, positive impact on product quality and safety.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

West Pharmaceutical Services, Inc.